Apple has teamed up with Eli Lilly on new research to detect evidence of brain decline by using data from connected devices such as the Apple Watch, reports CNBC.
The early-stage study took place over 12 weeks, and included both an 82-person healthy control group and 31 individuals with varying stages of cognitive decline and dementia. According to research published this week, the two companies teamed up with health-tech start-up Evidation to find ways to more quickly and precisely detect cognitive impairments like Alzheimer’s disease with the help of popular consumer gadgets.
Of the 15 authors of the paper, five work for each company with the other five representing Evidation. It’s the latest sign that Apple’s health team is investing in deep medical research with traditional pharmaceutical players, notes CNBC.
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Evidation is a health and measurement company that provides the biopharma and health care companies “the technology and guidance they need to understand how everyday behavior and health interact.”